Received metamizole sodium monohydrate with particle-size distribution D50 ≤ 150 µm and D90 ≤ 250 µm is directly suited for blending with microcrystalline cellulose PH102 at API loadings of 70–85% w/w only after moisture sorption is confirmed below 2.0% w/w by Ph. Eur. 2.2.32. The direct compression formulation is constrained by the brittle fracture behaviour of the API at compaction pressures above 150 MPa; therefore the lubricant system is limited to 0.5–1.0% w/w magnesium stearate blended separately through a 0.5 mm screen for 3–5 min in a 600 L bin blender. A representative batch uses 75.0% w/w metamizole sodium monohydrate, 14.5% w/w microcrystalline cellulose PH102, 5.0% w/w crospovidone type A, 3.0% w/w sodium starch glycolate, 0.5% w/w colloidal silicon dioxide, and 1.0% w/w magnesium stearate. Compression on a 45-station rotary tablet press with 12 mm round flat-faced bevel-edge punches uses pre-compression 5–8 kN, main compression 14–20 kN, turret speed 35–55 rpm, and force-feeder paddle speed 25–35 rpm; tablet hardness is held at 85–115 N, thickness 3.8–4.2 mm, friability ≤0.8% by Ph. Eur. 2.9.7, and disintegration ≤15 min by Ph. Eur. 2.9.1. In-process uniformity is verified by Ph. Eur. 2.9.40 at three intervals per batch; dissolution is tested in 900 mL deaerated water at 37 ± 0.5 °C, paddle 50 rpm, with sampling at 15 min, 30 min, and 45 min and a product-specific Q value of ≥80% at 30 min under ICH Q6A. Batch-to-batch variance in API bulk density between 0.45 g/mL and 0.60 g/mL is a known production bottleneck on high-speed presses; loss-in-weight feeder control and forced feeder paddle adjustment are required to prevent fill weight drift beyond ±3%. Compliance for this oral solid dosage route applies the current European Pharmacopoeia monograph for metamizole sodium monohydrate, ICH Q3D Table 1 element limits based on a 10 g/day maximum oral intake, ICH Q3C for any residual processing solvents, and EU GMP Part II / ICH Q7 for API handling. Terminal dosage type is a non-coated or aqueous film-coated tablet of 500 mg label claim, packed in PVC/aluminium or PA/Al/PVC blisters.

Why Does Wet Granulation Reduce Capping Defects in 500 mg Metamizole Sodium Tablets?

Metamizole sodium tablets formulated above 70% w/w by direct compression often display capping at hardness values above 100 N, caused by elastic recovery after decompression and low tensile strength of the compact. Moving to wet granulation changes the compaction mechanism by embedding API particles in a porous granule network. The formulation addition ratio for wet granulation is set at 55–68% w/w metamizole sodium monohydrate, 15–25% w/w lactose monohydrate 200M, 5–10% w/w maize starch, 2–4% w/w povidone K30 binder dissolved in purified water, 2–5% w/w croscarmellose sodium intra-granular, 0.5–1.0% w/w colloidal silicon dioxide, and 0.5–1.0% w/w magnesium stearate extra-granular. The high-shear wet granulation process uses a 600 L top-drive granulator with impeller speed 150–200 rpm, chopper 1500–2500 rpm, atomized purified water addition of 8–15% w/w at 0.5–1.0 kg/min, and a kneading time after water addition of 90–240 s until power consumption increases by 15–25% over the dry blend baseline. Overwetting above 15% w/w water produces large agglomerates that survive 1.0 mm screening and generate tablet hardness variability across the press. Wet granules are dried in a fluid-bed dryer with inlet air 55–70 °C and product temperature not exceeding 45 °C; final moisture is controlled at 1.5–2.5% w/w by Ph. Eur. 2.2.32. Dried granules are screened through 1.0 mm and mixed with extra-granular disintegrant. Tableting on a 45-station rotary press uses main compression 12–18 kN, hardness 120–180 N, friability ≤0.5%, and disintegration ≤15 min. Dissolution testing per Ph. Eur. 2.9.3 with 900 mL water, paddle 50 rpm, and acceptance ≥80% in 30 min applies; uniformity of dosage units follows Ph. Eur. 2.9.40. Compliance includes ICH Q3A and ICH Q3B degradation product thresholds calculated for a maximum daily intake of 4 g/day, ICH Q3D Table 1 elemental impurity limits, ICH Q1A(R2) stability for moisture-sensitive primary packaging, and current European Pharmacopoeia assay requirements. Published degradation kinetics data for aqueous granulation hold time of metamizole sodium beyond 6 h is limited; therefore, hold time studies are conducted as part of ICH Q1A(R2) process validation. Terminal dosage type is film-coated tablet 500 mg label claim, with aqueous film coating applied at 3–4% w/w weight gain.

Roller-compacted metamizole sodium granulate for hard capsule filling is produced when the batch size or regional packaging format favours two-piece capsules over tablets. The internal granulation uses 70–80% w/w metamizole sodium monohydrate, 10–18% w/w lactose monohydrate or pregelatinized starch, 3–5% w/w sodium starch glycolate, 1–2% w/w colloidal silicon dioxide, and 0.5–1.0% w/w magnesium stearate. Ribbon compaction on a 220K roller compactor with roll surface speed 5–15 rpm, hydraulic pressure 80–120 bar, and ribbon density 1.1–1.3 g/cm³ yields flakes that are milled through a 1.0 mm screen with an oscillating sieve mill. The milled granulate is passed through a 0.8 mm screen before final blending in a 400 L bin blender at 10 rpm for 20 min; bulk density is controlled at 0.55–0.65 g/mL and Carr index at 20–25 to prevent weight variation on dosator filling. Encapsulation is performed on a dosator-type capsule filler at 50,000–100,000 capsules/h using size 0 hard gelatin or HPMC capsules; fill weight 600–700 mg delivers 500 mg metamizole sodium per unit. Dosator capsule fillers show weight variation when granulate Carr index exceeds 25; hopper agitation and granulate temperature below 25 °C are used to limit electrostatic adhesion. Process controls include in-process fill weight checks at 15-min intervals, rejection of capsules outside ±5% of target fill weight, and metal detection at 0.3 mm ferrous sensitivity. Compliance includes Ph. Eur. 2.9.40 for uniformity of dosage units, Ph. Eur. 2.9.1 for disintegration, Ph. Eur. 2.9.3 dissolution in 900 mL water, ICH Q3D Table 1, ICH Q3C, and ICH M7 for mutagenic impurities; nitrosamine risk is controlled by testing N-nitrosodimethylamine and N-nitrosodiethylamine below regulatory interim limits. Terminal dosage type is hard capsule 500 mg, packed in PVC/PVDC/aluminium blisters or HDPE bottles with desiccant.

Water-Soluble Oral Granules in Single-Dose Sachets Under High-Daily-Dose Degradation Thresholds

Single-dose sachets containing metamizole sodium oral granules are formulated for rapid reconstitution in water, requiring a water-soluble carrier and strict moisture control. The addition ratio is 75–90% w/w metamizole sodium monohydrate, 5–15% w/w sucrose or sorbitol, 1–3% w/w citric acid, 0.5–1.0% w/w sodium saccharin, and 0.1–0.5% w/w flavour; the total fill mass per sachet is 1.0–2.0 g to deliver 500 mg metamizole sodium. Dry granulation by roller compaction is preferred over wet granulation because residual water above 1.5% w/w in the sachet leads to caking and reduced dispersion. The roller compactor operates at ribbon density 1.0–1.3 g/cm³, mill screen 0.8–1.25 mm, and the final granulate moisture is confirmed below 1.5% w/w by Ph. Eur. 2.2.32. Filling is performed on a vertical form-fill-seal sachet machine with nitrogen flush; heat-seal temperature 135–155 °C for aluminium-polyethylene laminate, residual oxygen ≤5% in headspace, and seal width ≥8 mm are monitored. Production experience shows that seal failures increase when powder dusting in the seal area exceeds 50 mg/cm², requiring vacuum extraction and periodic seal jaw cleaning. Uniformity of mass for single-dose granules follows Ph. Eur. 2.9.5; uniformity of content is verified by Ph. Eur. 2.9.40 when justified. Dispersion is evaluated by adding one sachet to 100 mL water at 25 ± 2 °C with stirring 50 rpm; complete dispersion occurs within 3 min because of the water-soluble formulation. Compliance includes ICH Q3B thresholds recalculated for a 4 g/day maximum daily intake, ICH Q3D Table 1 elemental impurities, and EU GMP Part II / ICH Q7. Terminal dosage type is single-dose oral granules in sachet, 500 mg.

When Terminal Moist-Heat Sterilization of Metamizole Sodium Injection Demands Impurity Re-Profiling

Injectable metamizole sodium is manufactured as a 500 mg/mL aqueous solution, corresponding to 50% w/v API concentration. The formula uses water for injection q.s., hydrochloric acid or sodium hydroxide for pH adjustment to 6.0–7.0, and, where terminal sterilization is selected, nitrogen blanketing to reduce oxidative degradation; some registered formulations include sodium metabisulfite at 0.01–0.05% w/v as oxygen scavenger, but sulfur exposure must be declared due to allergic cross-reactivity in patients. The compounding vessel is jacketed at 15–25 °C, and the API is added under vacuum to prevent foam; dissolution is confirmed by refractive index or density checks. Filtration passes the solution through a 0.45 µm prefilter and a 0.22 µm polyvinylidene fluoride sterilizing filter into Type I glass ampoules of 2 mL or 5 mL capacity. Terminal sterilization in a saturated steam autoclave at 121 °C for 15 min with F0 ≥8 is applied only after the degradation product profile is re-profiled; if any unidentified degradation product exceeds the ICH Q3B reporting threshold for the 4 g/day injectable maximum daily dose, aseptic processing without terminal heat is required. Ampoule neck cracking occurs when autoclave pressure equalization exceeds 2.0 bar during cooling; therefore, pressure ramp control and post-autoclave visual inspection for container integrity are mandatory. The filled ampoule solution is inspected for visible particles by Ph. Eur. 2.9.20, sub-visible particles by Ph. Eur. 2.9.19, bacterial endotoxins by Ph. Eur. 2.6.14 with the limit derived from the K/M calculation for the maximum bolus dose and route of administration, and sterility by Ph. Eur. 2.6.1. Compliance includes ICH Q3C for residual solvents, ICH Q3D Table 1 for elemental impurities using parenteral permitted daily exposures, and current European Pharmacopoeia parenteral preparation requirements. Published data for terminal sterilisation of metamizole sodium in ampoules across all pH conditions is limited; terminal sterilization therefore requires a product-specific degradation database before validation. Terminal dosage type is single-dose glass ampoule, 2 mL (1000 mg) and 5 mL (2500 mg) for slow intravenous or intramuscular administration.

For veterinary drinking-water administration, metamizole sodium is supplied as a water-soluble powder or granule premix with API loading of 20–50% w/w in a carrier of lactose monohydrate or glucose monohydrate. The field dose is adjusted to 10–30 mg/kg body weight per day, and the carrier blend is diluted in drinking water at a concentration not exceeding 2 g/L to prevent precipitation and intake variability. Production uses a horizontal band blender of 500 kg working capacity, paddle speed 12–18 rpm, mixing time 15–25 min, and post-mix uniformity tested on 10 stratified samples by HPLC; coefficient of variation ≤5% is the release criterion. Segregation occurs when carrier particle size difference exceeds 100 µm; therefore carriers are pre-sieved through 0.25 mm and matched to the API particle-size distribution. The powder is sieved through 0.5 mm, and moisture is controlled below 2.0% w/w by Ph. Eur. 2.2.32 to avoid channeling in volumetric dosing pumps. Packaging into 100 g, 500 g, and 1 kg polyethylene jars or laminated foil pouches includes heat-sealed desiccant. Compliance is governed by EU GMP for veterinary medicinal products, VICH GL 18 for residual solvents, and Ph. Eur. 2.2.32 for moisture; published data for specific metamizole sodium premix stability under tropical field conditions is limited, so accelerated stability is required at 40 ± 2 °C / 75 ± 5% RH. Terminal dosage type is water-soluble powder or granule for oral administration in drinking water, supplied as 100 g, 500 g, or 1 kg packs.